Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week results from the ESTEEM 2 study

Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2015
This article has no abstract
Epistemonikos ID: 0d6c02a1a20785887b25acf0a7735621ed8be966
First added on: Feb 07, 2025